Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Large Drop in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totaling 25,074 shares, a decrease of 64.5% from the August 31st total of 70,645 shares. Based on an average trading volume of 214,273 shares, the short-interest ratio is currently 0.1 days. Currently, 0.0% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Zacks Research cut Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Astellas Pharma presently has a consensus rating of “Moderate Buy”.

Astellas Pharma Stock Down 2.2%

Astellas Pharma stock traded down $0.34 during mid-day trading on Monday, reaching $14.88. 19,623 shares of the company’s stock were exchanged, compared to its average volume of 155,912. The company has a market cap of $26.93 billion, a P/E ratio of 11.32 and a beta of 0.08. Astellas Pharma has a twelve month low of $10.03 and a twelve month high of $17.35. The company has a quick ratio of 0.93, a current ratio of 1.20 and a debt-to-equity ratio of 0.16. The company has a fifty day moving average of $14.55 and a 200-day moving average of $14.53.

About Astellas Pharma

Astellas Pharma Inc is a Japan-based pharmaceutical company that discovers, develops and commercializes prescription medicines for serious and unmet medical needs. Its research and commercial activities focus on areas including oncology, urology, immunology, neuromuscular diseases, ophthalmology and other specialty conditions.

The company’s portfolio includes treatments such as XTANDI for certain prostate cancers, XOSPATA for acute myeloid leukemia, MYRBETRIQ for overactive bladder and VEOZAH for menopausal hot flashes.